Jemperli (dostarlimab) Effective 03/01/2025
Covers prior authorization, clinical criteria, continuation, and limits for Jemperli (dostarlimab) for commercial/exchange plans (MassHealth UPPL Plan references) including indications: dMMR recurrent/advanced solid tumors, dMMR recurrent/advanced endometrial cancer, and primary advanced or recurrent endometrial cancer (combination with carboplatin + paclitaxel followed by monotherapy).
Added supplemental indication of primary advanced or current endometrial cancer.
Updated criteria for primary advanced or recurrent endometrial cancer to clarify when Jemperli should be used in the regimen.
Removed requirement for appropriate dosing and updated specialist prescriber verbiage; updated verbiage for members new to the plan.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.